Definition And Composition

  • Combination vaccine containing multiple immunogens physically combined in single preparation.
  • Incorporates Diphtheria, Tetanus, Whole-cell Pertussis (DTwP), Hepatitis B, and Haemophilus influenzae type b (Hib).
  • Antigens adsorbed onto insoluble aluminum salts acting as adjuvants.
  • Available brands include Pentavac PFS, Comvac-5, ComBE Five, Shan-5, and Easyfive-TT.

Antigenic Content Matrix

Antigen ComponentConcentration/Dose
Diphtheria toxoid≥20 to ≤30 Limit of flocculation
Tetanus toxoid≥2.5 to ≤25 Limit of flocculation
Whole-cell Pertussis≥4 International Units
Haemophilus influenzae type b (PRP conjugate)10 Micrograms
Hepatitis B surface antigen10 Micrograms

Advantages And Public Health Impact

  • Reduces number of injections administered during single visit.
  • Decreases required office visits and potential administrative costs.
  • Simplifies packaging, storage, and transportation.
  • Enhances overall immunization coverage.
  • Replaced standard DPT vaccine to improve Haemophilus influenzae type b vaccination rates.
  • Significantly reduced Haemophilus influenzae type b meningitis cases following Universal Immunization Program introduction.

Administration Details

  • Dose measures exactly 0.5 milliliters.
  • Administered strictly intramuscularly.
  • Preferred site remains anterolateral aspect of mid-thigh.

Storage And Cold Chain Requirements

  • Requires strict storage at 2 to 8 degrees Celsius.
  • Classified as freeze-sensitive vaccine due to adsorbed aluminum adjuvants.
  • Accidental freezing mandates immediate discarding.
  • Shake test detects erroneous freezing.
  • Stored in middle shelves of ice-lined refrigerators.

Immunization Schedule

  • Introduced into Universal Immunization Program in phased manner since 2011.
  • Administered primarily at 6, 10, and 14 weeks of age.
  • First dose acts as priming dose despite maternal antibodies.
  • Permitted for administration up to 1 year of age.
  • Induces excellent immunity lasting till second year of life.
  • Booster dose at 15 to 18 months utilizes DTwP and Haemophilus influenzae type b combination.

Adverse Effects And Precautions

  • Minor events include local pain, swelling, redness, fever, fussiness, anorexia, and vomiting.
  • Reactions predominantly attributed to whole-cell pertussis component.
  • Postmarketing surveillance confirmed no causal link to severe adverse events or deaths.
  • Absolute contraindication involves severe allergic reaction or anaphylaxis to previous dose or vaccine component.